From evidence-based medicine to personalized medicine, with particular emphasis on drug-safety monitoring

1948, Streptomycin treatment of pulmonary tuberculosis. A medical research council investigation, Br Med J, 2, 769, 10.1136/bmj.2.4582.769 Barritt, 1960, Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial, Lancet, 1, 1309, 10.1016/S0140-6736(60)92299-6 Jerjes-Sanchez, 1995, Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial, J Thromb Thrombolysis, 2, 227, 10.1007/BF01062714 1987, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group, N Engl J Med, 316, 1429 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators, N Engl J Med, 327, 685, 10.1056/NEJM199209033271003 Ennezat, 2011, Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction, Expert Opin Pharmacother, 12, 883, 10.1517/14656566.2011.543675 Ferrari, 2006, Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study, Arch Intern Med, 166, 659, 10.1001/archinte.166.6.659 Stone, 2008, Bivalirudin during primary PCI in acute myocardial infarction, N Engl J Med, 358, 2218, 10.1056/NEJMoa0708191 Leonardi, 2012, Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial, Am Heart J, 163, 768, 10.1016/j.ahj.2012.02.018 Bhatt, 2013, Effect of platelet inhibition with cangrelor during PCI on ischemic events, N Engl J Med, 368, 1303, 10.1056/NEJMoa1300815 Teerlink, 2013, Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial, Lancet, 381, 29, 10.1016/S0140-6736(12)61855-8 Moncrieff, 2004, Active placebos versus antidepressants for depression, Cochrane Database Syst Rev, CD003012 Swedberg, 2010, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, Lancet, 376, 875, 10.1016/S0140-6736(10)61198-1 Bhatt, 2014, A controlled trial of renal denervation for resistant hypertension, N Engl J Med, 370, 1393, 10.1056/NEJMoa1402670 Staessen, 1997, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators, Lancet, 350, 757, 10.1016/S0140-6736(97)05381-6 Yusuf, 2016, Cholesterol lowering in intermediate-risk persons without cardiovascular disease, N Engl J Med, 374, 2021, 10.1056/NEJMoa1600176 Vestbo, 2016, Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice, N Engl J Med, 375, 1253, 10.1056/NEJMoa1608033 Wright, 1998, Gains in life expectancy from medical interventions – standardizing data on outcomes, N Engl J Med, 339, 380, 10.1056/NEJM199808063390606 Finegold, 2016, Distribution of lifespan gain from primary prevention intervention, Open Heart, 3, e000343, 10.1136/openhrt-2015-000343 Bassler, 2010, Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis, JAMA, 303, 1180, 10.1001/jama.2010.310 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646 Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 Pitt, 1997, Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE), Lancet, 349, 747, 10.1016/S0140-6736(97)01187-2 Pitt, 2000, Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II, Lancet, 355, 1582, 10.1016/S0140-6736(00)02213-3 Lalani, 2015, Cardiac resynchronisation therapy in patients with chronic heart failure, Heart, 101, 1008, 10.1136/heartjnl-2014-306835 Tung, 2008, A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death, J Am Coll Cardiol, 52, 1111, 10.1016/j.jacc.2008.05.058 Samson, 2014, Systolic heart failure: knowledge gaps, misconceptions, and future directions, Ochsner J, 14, 569 Kober, 2016, Defibrillator implantation in patients with nonischemic systolic heart failure, N Engl J Med, 375, 1221, 10.1056/NEJMoa1608029 Fox, 2003, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study), Lancet, 362, 782, 10.1016/S0140-6736(03)14286-9 Steg, 2012, ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, Eur Heart J, 33, 2569, 10.1093/eurheartj/ehs215 Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Juurlink, 2004, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study, N Engl J Med, 351, 543, 10.1056/NEJMoa040135 Desmaele, 2016, Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?, Eur J Clin Pharmacol, 72, 1125, 10.1007/s00228-016-2078-1 Nicot, 2015, La pharmacovigilance : une mission indispensable des médecins de terrain, Med Ther, 21, 155 Munroe, 1969, Mitral regurgitation occurring during methsergide (Sansert) therapy, Can Med Assoc J, 101, 62 Connolly, 1997, Valvular heart disease associated with fenfluramine-phentermine, N Engl J Med, 337, 581, 10.1056/NEJM199708283370901 Bolland, 2016, Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency, BMJ, 354, i5109, 10.1136/bmj.i5109 McMurray, 2014, Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, 371, 993, 10.1056/NEJMoa1409077 Feldman, 2016, Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations, JAMA, 315, 25, 10.1001/jama.2015.17632 Lazarus, 2016, Proton pump inhibitor use and the risk of chronic kidney disease, JAMA Intern Med, 176, 238, 10.1001/jamainternmed.2015.7193 Mendes, 2016, Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit–risk evaluations: case study with medicines withdrawn from the European market due to safety reasons, Expert Opin Drug Saf, 15, 1301, 10.1080/14740338.2016.1217989 Onakpoya, 2015, Delays in the postmarketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis, BMC Med, 13, 26, 10.1186/s12916-014-0262-7 Grady, 2010, Less is more: how less health care can result in better health, Arch Intern Med, 170, 749, 10.1001/archinternmed.2010.90